COVID-19 immunity may help protect against other bat coronaviruses
· Medical Xpressedited by Sadie Harley, reviewed by Robert Egan
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Senior Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
People who recovered from COVID-19 infection or were vaccinated against SARS-CoV-2 are more likely to have immunity to other closely related bat coronaviruses that could threaten future human health.
In a joint study by The Pirbright Institute and King's College London (KCL), scientists found that bat coronaviruses most likely to infect a wide range of animal species are those most closely related to SARS-CoV-2 and most likely to be recognized by immunity generated through COVID-19 infection.
The research is published in two companion articles in PLOS Biology.
Close relatives can infect more host species
Researchers examined how a diverse group of bat sarbecoviruses—the coronavirus subgroup that includes SARS-CoV-1 and SARS-CoV-2—interact with ACE2, the cellular receptor used by many coronaviruses to enter host cells.
They investigated the ability of these viruses to use ACE2 proteins from a broad range of bat and mammalian species, including humans, livestock, rodents and animals previously proposed as intermediate hosts.
The team discovered that so-called "generalist" sarbecoviruses, which can use ACE2 receptors from many different species, were largely confined to the same evolutionary group as SARS-CoV-2.
Pirbright postdoctoral scientist and lead author Dr. Nazia Thakur said, "Our findings suggest that the bat coronaviruses currently considered most likely to spill over into humans are also most likely to be recognized by existing COVID-19 immunity. While spillover risk can never be eliminated, widespread exposure to SARS-CoV-2 may have raised the barrier for related viruses to establish themselves in human populations."
The team analyzed 15 representative bat coronavirus spike proteins using libraries of ACE2 receptors from 34 species. Broad ACE2 usage was a defining feature of viruses closely related to SARS-CoV-2, including the BANAL viruses discovered in Laos.
Viruses from other evolutionary groups, including a novel U.K. bat coronavirus, RhGB07, showed more restricted receptor usage. To aid in their analyses, the spike structure of RhGB07 was also resolved by collaborators in Switzerland.
The study also investigated how the SARS-CoV-2 host range evolved during the pandemic. Researchers found that variants, particularly those within the omicron lineage, acquired mutations in the receptor-binding domain that resulted in shifting patterns of ACE2 usage across animal species, highlighting the dynamic relationship between viral evolution and host susceptibility.
COVID-19 antibodies neutralize related bat coronaviruses
To understand the implications for human health, the scientists examined blood samples from people who had recovered from COVID-19. Antibodies in these samples successfully neutralized a range of closely related bat coronaviruses. Researchers also detected lower levels of neutralization against more distant bat sarbecoviruses, suggesting some degree of broader protection.
Katie Doores, professor of viral immunology at KCL, said, "These viruses showed the strongest antigenic similarity to SARS-CoV-2, meaning they were more readily recognized and neutralized by antibodies generated following COVID-19 infection. In contrast, more distantly related bat coronaviruses tended to be 'specialists,' capable of using ACE2 receptors from only a limited range of hosts."
Shared spike regions offer broader vaccine targets
Further experiments at KCL and Pirbright identified several monoclonal antibodies capable of recognizing a diverse range of sarbecoviruses. The second companion article identified where these monoclonal antibodies bind, highlighting conserved regions of the coronavirus spike protein and offering important clues for the development of next-generation vaccines and therapeutics.
Dr. Dalan Bailey, head of Pirbright's Viral Glycoproteins group, added, "One of the encouraging findings was evidence of cross-neutralization of even some of the more distantly related bat coronaviruses. This suggests that broadly protective, pan-sarbecovirus vaccines or therapeutics may be achievable."
The work highlights the importance of understanding virus host range, receptor usage and immune recognition together rather than in isolation. By identifying characteristics that distinguish higher-risk viruses from those less likely to spill over into humans, researchers hope to strengthen global pandemic preparedness efforts.
Publication details
Nazia Thakur et al, Breadth of ACE2 receptor usage predicts host range and antigenic relatedness across bat sarbecoviruses, PLOS Biology (2026). DOI: 10.1371/journal.pbio.3003944
Ayush Upadhyay et al, Targeting of conserved spike epitopes enables broad antibody neutralisation of diverse bat sarbecoviruses, PLOS Biology (2026). DOI: 10.1371/journal.pbio.3003882
Journal information: PLoS Biology
Key medical concepts
Clinical categories
Infectious diseasesCommon illnesses & Prevention Provided by The Pirbright Institute Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: COVID-19 immunity may help protect against other bat coronaviruses (2026, October 1) retrieved 1 October 2026 from https://medicalxpress.com/news/2026-10-covid-immunity-coronaviruses.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.